Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Arvisol

(Tivantinib)

Phase 3Small molecule

Tivantinib is used to treat a type of liver cancer called hepatocellular carcinoma in patients who have already tried other treatments. It works by slowing or stopping the growth of cancer cells.[1] Arvisol is currently being investigated across 19 indications[3], with its most advanced program in Phase 3.[1]

Arvisol is one of 505 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

19

Indications

22

Total Trials

0

Active Trials

504

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Kidney CancerActive, not recruiting

Lung CancerActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Germ Cell TumorActive, not recruiting

AdenocarcinomaActive, not recruiting

MesotheliomaActive, not recruiting

Malignant MesotheliomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Liver CancerActive, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

Germ Cell TumorPhase 2

Active, not recruiting

AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

MesotheliomaPhase 2

Active, not recruiting

Malignant MesotheliomaPhase 2

Active, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Liver CancerPhase 3

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Arvisol

Tykerb

Megace

Bristol-Myers Squibb

MS Contin

Chantix

PPrism Pharmaceuticals

Avastin

Chirocaine

PPurdue Pharma LP

Vfend

PPrism Pharmaceuticals

Neoadjuvant Therapy

SSun Yat-sen University

QS21

MMemorial Sloan Kettering Cancer Center

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Patients With Solid Tumors2 trials

Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01625156·11 enrolled

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01749384·12 enrolled

Advanced Solid Tumors2 trials

Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT02150733·29 enrolled

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT01149720·24 enrolled

Refractory Solid Tumors1 trial

Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01725191·36 enrolled

Metastatic Colorectal Cancer1 trial

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT01075048·131 enrolled

Kidney Cancer1 trial

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01688973·55 enrolled

15 more indications

Interaction1 trial

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT01517399·28 enrolled

Carboplatin1 trial

Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin

Completed·—·Phase 1/2·NCT02049060·31 enrolled

Advanced or Metastatic Solid Tumors1 trial

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01654965·17 enrolled

Multiple Myeloma1 trial

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01447914·16 enrolled

Head and Neck Cancer1 trial

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01696955·81 enrolled

Breast Cancer1 trial

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01575522·22 enrolled

Malignant Mesothelioma1 trial

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01861301·18 enrolled

Hepatocellular Carcinoma1 trial

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT01755767·383 enrolled

Adenocarcinoma1 trial

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT01611857·49 enrolled

Metastatic Prostate Cancer1 trial

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01519414·78 enrolled

EGFR1 trial

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Completed·—·Phase 2·NCT01892527·43 enrolled

Germ Cell Tumor1 trial

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT01055067·27 enrolled

Lung Cancer1 trial

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT01244191·1,048 enrolled

Cancer1 trial

Effect of Tivantinib on the QTC Interval in Cancer Subjects

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT01699061·38 enrolled

Unspecified1 trial

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT01178411·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Tivantinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tivantinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tivantinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Hepatocyte Growth Factor Receptor Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Daiichi Sankyo

Related News